BerGenBio ASA: Invitation to First Quarter 2018 Results Presentation and Webcast
Bergen, Norway, 08 May 2018- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib (BGB324), a first-in-class selective small molecule AXL inhibitor, as a potential cornerstone therapy for multiple cancer indications, will announce its results for the first quarter 2018 on Tuesday, 15 May 2018. A presentation by BerGenBio's senior management team will take place at 10:00 am CET at:Felix Konferansesenter, Bryggetorget 3, 0125 Oslo The presentation will webcast live and the link will be available at www.bergenbio.com in the section